Elevating Expectations: Risankizumab’s Impact on Revolutionizing Psoriatic Arthritis Care

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that is associated with psoriasis (PsO) and affects about 20% of patients with psoriasis. PsA is characterized by a wide range of symptoms that can vary over time, affecting both the musculoskeletal system as well as the skin and nails. The heterogeneity of PsA means that patients might experience fluctuating and diverse manifestations of the disease, requiring a nuanced approach to treatment. In light of this, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) released their 2021 treatment recommendations, which emphasize the importance of individualized therapy based on six specific domains: peripheral arthritis, enthesitis, dactylitis, axial disease, psoriasis, and nail disease. This domain-based approach is designed to address the multifaceted nature of PsA, ensuring that treatment is tailored to the specific clinical manifestations present in each patient. Following this, the European Alliance of Associations for Rheumatology (EULAR) in their 2023 PsA treatment recommendations also adopted a similar approach. They provided strong endorsements for newer therapeutic classes, such as Interleukin-23 inhibitors (IL-23i), particularly in the treatment of peripheral arthritis, significant skin involvement, and enthesitis. Risankizumab stands out as the most recently approved IL-23 inhibitor for the treatment of PsA. Its mechanism of action involves specifically binding to the p19 subunit of IL-23, thereby blocking downstream signaling pathways and suppressing inflammatory responses. Recent analyses have demonstrated Risankizumab’s consistent efficacy across various patient demographics and disease characteristics, making it a versatile and effective option for managing PsA. In this context, Professor Östör will present key trial data and share case experiences with IL-23 inhibitors across the different manifestations of PsA. The aim of this lecture is to enhance the understanding of how to tailor treatment plans according to individual patient preferences and clinical profiles. By delving into these data and case studies, Professor can provide valuable insights into optimizing treatment strategies, ultimately leading to improved patient satisfaction and overall disease control.